



Data on Anti-CD19 Compound, XmAb(r)5574, Published in Blood Journal

February 18, 2010

Data on our lead anti-CD19 compound targeting B-cell malignancies, XmAb(r)5574, was published last week in Blood in a paper titled, "CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody." The paper describes the activity and mechanism of XmAb(r)5574 against leukemia cells and the potential for its use in leukemia therapy. The abstract is available on the Xencor Web site here <<http://www.xencor.com/news-publications.html>>, and access to the full text is available here <<http://bloodjournal.hematologylibrary.org/cgi/content/abstract/115/6/1204>> .

Please let us know if you have any questions.

Xencor, Inc.